АНАЛІЗ ЩІЛЬНОСТІ ІНТЕГРАЦІЇ ГІПЕРУРИКЕМІЇ В КЛАСТЕР ФАКТОРІВ РИЗИКУ ПОРУШЕНЬ ГЛЮКОЗНОГО ГОМЕОСТАЗУ, АСОЦІЙОВАНИХ З МЕТАБОЛІЧНИМ СИНДРОМОМ НА РІВНІ ВИПАДКОВОЇ ПОПУЛЯЦІЙНОЇ ВИБІРКИ

Anna Cherniaieva; Myroslava Mykytyuk; Yuri Karachentsev

doi:10.21856/j-PEP.2026.1.05

DENSITY ANALYSIS OF THE INTEGRATION OF HYPERURICEMIA INTO THE CLUSTER OF RISK FACTORS FOR GLUCOSE HOMEOSTASIS DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AT THE LEVEL OF A RANDOM POPULATION SAMPLE

Authors

Cherniaieva A. O. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine»; Kharkiv, Ukraine; Kharkiv National Medical University, Kharkiv, Ukraine https://orcid.org/0000-0002-2812-3323
Mykytyuk M. R. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine»; Kharkiv, Ukraine https://orcid.org/0000-0002-6169-7628
Karachentsev SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine»; Kharkiv, Ukraine; Kharkiv National Medical University, Kharkiv, Ukraine https://orcid.org/0000-0003-1317-6999

DOI:

https://doi.org/10.21856/j-PEP.2026.1.05

Keywords:

uric acid, hyperuricemia, purine dysmetabolism, insulin resistance, metabolic syndrome, impaired glucose homeostasis, random population sample, obesity, cardiovascular risk

Abstract

Background. Hyperuricemia, as one of the key components of the metabolic syndrome in the population, can be assessed only under certain conditions. Hyperuricemia in the context of the metabolic syndrome is understood as a serum uric acid concentration in accordance with population norms. At the same time, according to the EULAR recommendations, the criteria for verification of hyperuricemia are more stringent and aimed at diagnosing gout, in which the serum uric acid concentration is pathologically high.
Research objective – to analyze the density of integration of hyperuricemia into the cluster of risk factors for glucose homeostasis disorders associated with metabolic syndrome, and to provide a quantitative assessment of the relationship between hyperuricemia and the main components of metabolic syndrome at the level of a random population sample.
Materials and methods. According to generally accepted epidemiological approaches random population sample of 727 individuals was formed. Metabolic syndrome was diagnosed according to IDF criteria (2006).
Results. Hyperuricemia (HU) was detected in 16.23 % of people in the studied random population sample (RPS). It was found that with. The relationship between serum uric acid (UA) concentration and age, the studied parameters of glucose homeostasis, blood lipid spectrum, cardiovascular risk, liver and kidney function in RPS representatives with overweight/obesity (BMI ≥25 kg/m²) does not depend on any of the selected stratification criteria (gender, BMI, and degree of obesity). Each of the selected clinical and biochemical parameters can be considered both a cause and a consequence of HU in overweight/obese individuals in the RPS. According to the results of factor analysis, it was determined that serum UA concentration in RPS representatives is associated with age, abdominal obesity, liver and kidney function. The established density of the connection of the HU with other components of the metabolic syndrome does not allow considering the HU as a component of the metabolic syndrome in the RPS.
Conclusions. Hyperuricemia in random population sample representatives is associated with age, abdominal obesity and insulin resistance and is not related to the "classic" components of metabolic syndrome (glucose homeostasis disorders, arterial hypertension, dyslipidemia) and does not act as a synergistic factor between them. In random population sample representatives with excess body weight/obesity, regardless of gender, serum uric acid concentration is associated with age, parameters of glucose homeostasis, blood lipid spectrum, with cardiovascular risk, functional state of the liver and kidneys.

References

1. Kurajoh M, Fukumoto S, Yoshida S, et al. Sci Rep 2021;11(1): 7378. https://doi.org/10.1038/s41598-021-86962-0

2. Watanabe S, Kang DH, Feng L, et al. Hypertension 2002;40(3): 355-360. https://doi.org/10.1161/01.hyp.0000028589.66335.aa

3. Oda M, Satta Y, Takenaka O, et al. Mol Biol Evol 2002;19(5): 640-653. https://doi.org/10.1093/oxfordjournals.molbev.a004123

4. Sun HL, Pei D, Lue KH, et al. PLoS One 2015;10(11): e0143786. https://doi.org/10.1371/journal.pone.0143786

5. Gagliardi AC, Miname MH, Santos RD. Atherosclerosis 2009;202(1): 11-17. https://doi.org/10.1016/j.atherosclerosis.2008.05.022

6. van der Schaft N, Brahimaj A, et al. PLoS One 2017;12(6): e0179482. https://doi.org/10.1371/journal.pone.0179482

7. Ohno I. Nucleosides Nucleotides Nucleic Acids 2011;30(12): 1039-1044. https://doi.org/10.1080/15257770.2011.611484

8. Zhang S, Wang Y, Cheng J, et al. Curr Pharm Des 2019;25(6): 700-709. https://doi.org/10.2174/1381612825666190408122557

9. Pareek V, Pedley AM, Benkovic SJ. Crit Rev Biochem Mol Biol 2021;56(1): 1-16. https://doi.org/10.1080/10409238.2020.1832438

10. Scuiller A, Pascart T, Bernard A, et al. Rev Med Interne 2020;41(6): 396-403. https://doi.org/10.1016/j.revmed.2020.02.014

11. Zhang W, Doherty M, Bardin T, et al. Ann Rheum Dis 2006;65(10): 1312-1324. https://doi.org/10.1136/ard.2006.055269

12. Richette P, Doherty M, Pascual E, et al. Ann Rheum Dis 2017;76(1): 29-42. https://doi.org/10.1136/annrheumdis-2016-209707

13. Alberti KG, Zimmet P, Shaw J. Diabet Med 2006;23(5): 469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x

14. Vargas-Santos AB, Taylor WJ, Neogi T. Curr Rheumatol Rep 2016;18(7): 46. https://doi.org/10.1007/s11926-016-0594-8

15. American Diabetes Association Professional Practice Committee. Diabetes Care 2024;47(1): S20-S42. https://doi.org/10.2337/dc24-S002

16. Gardner AW, Alaupovic P, Parker DE, et al. Vasc Med 2013;18(3): 129-135. https://doi.org/10.1177/1358863X13489768

17. Matthews DR, Hosker JP, Rudenski AS, et al. Diabetologia 1985;28(7): 412-419. https://doi.org/10.1007/BF00280883

18. Wallace TM, Levy JC, Matthews DR. Diabetes Care 2004;27(6): 1487-1495. https://doi.org/10.2337/diacare.27.6.1487

19. Zhang M, Zhu X, Wu J, et al. Front Immunol 2022;12: 791983. https://doi.org/10.3389/fimmu.2021.791983

20. Kuwabara M, Kuwabara R, Niwa K, et al. Nutrients 2018;10(8): 1011. https://doi.org/10.3390/nu10081011

21. Kim SK, Choe JY. Medicine (Baltimore) 2019;98(7): e14507. https://doi.org/10.1097/MD.0000000000014507

22. Ulutaş F, Bozdemir A, Çelikyürek NA, et al. Mediterr J Rheumatol 2021;32(3): 243-248. https://doi.org/10.31138/mjr.32.3.243

23. Takagi K, Nakamura T, Ueda T. Nihon Rinsho 2008;66(4): 669-674, available at: https://pubmed.ncbi.nlm.nih.gov/18409512/

24. Babić-Ivancić V, Jendrić M, Sostarić N, et al. Coll Antropol 2010;34(1): 259-266, available at: https://pubmed.ncbi.nlm.nih.gov/20402330/

25. Chhana A, Lee G, Dalbeth N. BMC Musculoskelet Disord 2015;16: 296. https://doi.org/10.1186/s12891-015-0762-4

26. Mandal AK, Mount DB. Annu Rev Physiol 2015;77: 323-345. https://doi.org/10.1146/annurev-physiol-021113-170343

27. Estiverne C, Mandal AK, Mount DB. Semin Nephrol 2020;40(6): 535-549. https://doi.org/10.1016/j.semnephrol.2020.12.006

28. Bardin T, Richette P. Curr Opin Rheumatol 2014;26(2): 186-191. https://doi.org/10.1097/BOR.0000000000000028

29. Cai Z, Xu X, Wu X, et al. Asia Pac J Clin Nutr 2009;18(1): 81-87, available at: https://pubmed.ncbi.nlm.nih.gov/19329400/

30. Jiao XF, Song K, Jiao X, et al. Front Pharmacol 2023;13: 1045561. https://doi.org/10.3389/fphar.2022.1045561

31. Finnikin S, Mallen CD, Roddy E. BMC Prim Care 2023;24(1): 246. https://doi.org/10.1186/s12875-023-02201-7

32. Jia E, Zhu H, Geng H, et al. Trials 2022;23(1): 745. https://doi.org/10.1186/s13063-022-06695-x

33. Pou MA, Orfila F, Pagonabarraga J, et al. Joint Bone Spine 2022;89(6): 105402. https://doi.org/10.1016/j.jbspin.2022.105402

34. Rohm TV, Meier DT, Olefsky JM, et al. Immunity 2022;55(1): 31-55. https://doi.org/10.1016/j.immuni.2021.12.013

35. Copur S, Demiray A, Kanbay M. Eur J Intern Med 2022;103: 4-12. https://doi.org/10.1016/j.ejim.2022.04.022

36. de Oliveira EP, Burini RC. Diabetol Metab Syndr 2012;4: 12. https://doi.org/10.1186/1758-5996-4-12

37. Stamp LK, Turner R, Khalilova IS, et al. Rheumatology (Oxford) 2014;53(11): 1958-1965. https://doi.org/10.1093/rheumatology/keu218

38. Yanai H, Adachi H, Hakoshima M, et al. Int J Mol Sci 2021;22(17): 9221. https://doi.org/10.3390/ijms22179221

39. Syed AAS, Fahira A, Yang Q, et al. Genes (Basel 2022;13(4): 557. https://doi.org/10.3390/genes13040557

40. Nieradko-Iwanicka B. Crit Rev Food Sci Nutr 2022;62(25): 7129-7137. https://doi.org/10.1080/10408398.2021.1911928

Additional Files

PDF UA (Українська)

Published

2026-03-15

How to Cite

Cherniaieva, A., Mykytyuk, M., & Karachentsev, Y. (2026). DENSITY ANALYSIS OF THE INTEGRATION OF HYPERURICEMIA INTO THE CLUSTER OF RISK FACTORS FOR GLUCOSE HOMEOSTASIS DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AT THE LEVEL OF A RANDOM POPULATION SAMPLE. Problems of Endocrine Pathology, 83(1), 42–51. https://doi.org/10.21856/j-PEP.2026.1.05